PFS was the PRIMARY endpoint of the trial and DCVax-L failed to meet it. PFS was the AGREED to endpoint by both the FDA and NWBO. Only when NWBO saw they were going to fail to meet it, they change the protocol and tossed out the PFS primary endpoint. FDA knew it and that's why NWBO didn't file an FDA application.
Market Data 
Markets 
AI
